Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs

Area of Science:

• Neuroscience
• Genetics
• Regenerative Medicine

Background:

• Canavan disease (CD) is a fatal genetic leukodystrophy caused by ASPA gene mutations.
• It leads to N-acetyl-L-aspartate (NAA) accumulation, demyelination, and severe neurological deficits.
• Currently, no cure or standard treatment exists for Canavan disease.

Purpose of the Study:

• To develop a human induced pluripotent stem cell (iPSC)-based cell therapy for Canavan disease.
• To engineer patient-derived neural progenitor cells (iNPCs) or oligodendrocyte progenitor cells (iOPCs) with a functional ASPA gene.
• To evaluate the therapeutic efficacy of these engineered cells in a mouse model of Canavan disease.

Main Methods:

• Lentiviral transduction or TALEN-mediated gene editing was used to introduce the functional ASPA gene into patient iPSCs.
• Generated ASPA-engineered iNPCs or iOPCs were stereotactically transplanted into a Canavan disease mouse model.
• Therapeutic effects were assessed by measuring ASPA activity, NAA levels, neuropathology, myelination, motor function, and survival.

Main Results:

• Transplanted ASPA-engineered cells successfully corrected deficient ASPA activity and reduced elevated NAA levels in the mouse model.
• Major pathological features of Canavan disease, including vacuolation and defective myelination, were significantly rescued.
• Engrafted cells promoted robust and sustainable recovery of motor function and markedly prolonged survival in transplanted mice.

Conclusions:

• Genetically engineered patient iPSC-derived cells represent a promising cell therapy for Canavan disease.
• This approach offers a potential first-ever treatment for children with Canavan disease.
• The methodology may also be applicable to other fatal genetic disorders lacking effective therapies.